Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
Based on outcomes reported by patients, increased fatigue may predict disease progression in relapsed CLL / SLL patients on ibrutinib or zanubrutinib.
Fatigue is one of the most common symptoms experienced by those living with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), and it is also commonly overlooked, underreported, and undertreated.
Fatigue is one of the most common symptoms experienced by those living with CLL and SLL, and it is also commonly overlooked,underreported, and undertreated.
Ask the Doctor Question: I was diagnosed with CLL in 2015 and on watch and wait, with good bloods. I am Stage A/0. I was a Specialist Biomedical Scientist in the
In his book, Dr. Nabhan acknowledges the invaluable role care partners play for their loved ones living with CLL and the toll doing so can have.
Blocking the BTK pathway transformed treatment for CLL, but resistance can develop. The BTK degrader destroys it with two-thirds of patients responding.
Combining the new BCL2 inhibitor sonrotoclax with the BTK inhibitor zanubrutinib produced an overall response rate of 97% in relapsed CLL / SLL.
The combination of pirtobrutinib, venetoclax, and rituximab was very effective and produced deep remissions in patients with relapsed / refractory CLL.
People with CLL and SLL are at higher risk of developing infections due to having weakened immune systems.
One click to our most popular content.
